To evaluate the relevance of the MT1‐MMP/TSP1/nitric oxide pathway in colitis in vivo, we first injected intraperitoneally the C‐terminal E123CaG‐1 TSP1 fragment (containing CD47 and αvβ3 integrin binding sites) into MT1iΔEC mice and observed that it significantly increased the number of IA events 3 days post‐1% DSS treatment compared with mice treated with full‐length TSP1 (Fig EV5F and G). Here, MMP14 is linked to colitis.